Results 51 to 60 of about 3,097,477 (208)

Decreased Hepatic Nerve Fiber Innervation in Patients with Liver Cirrhosis

open access: yes, 2020
Background/Aims: Hepatic nerve innervation plays important roles in hepatic metabolism and hemodynamic mechanisms. We compared the distribution patterns of hepatic nerves between normal livers and two liver diseases to elucidate the effects of liver ...
유권, 김태헌, 정규원
core  

EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease

open access: yes, 2016
The Clinical Practice Guidelines propose recommendations for the diagnosis, treatment and follow-up of non-alcoholic fatty liver disease (NAFLD) patients and are the product of a joint effort by the European Association for the Study of the Liver (EASL),
MARCHESINI REGGIANI, GIULIO   +2 more
core   +1 more source

SQSTM1/p62 in intrahepatic cholangiocarcinoma promotes tumor progression via epithelial–mesenchymal transition and mitochondrial function maintenance

open access: yesCancer Medicine, 2023
Background SQSTM1/p62 is a selective autophagy receptor that regulates multiple signaling pathways participating in the initiation and progression of tumors.
Jiafeng Chen   +15 more
doaj   +1 more source

Combination of Transient Elastography and an Enhanced Liver Fibrosis Test to Assess the Degree of Liver Fibrosis in Patients with Chronic Hepatitis B [PDF]

open access: yes, 2018
Background/Aims: Liver stiffness (LS) was assessed using transient elastography, and the enhanced liver fibrosis (ELF) test was performed to accurately assess fibrotic burden.
안상훈   +5 more
core   +1 more source

Impact of the 2024 medical-policy conflict on hepatocellular carcinoma management in Korea [PDF]

open access: yesJournal of Liver Cancer
In 2024, a nationwide conflict between the South Korean government and the medical community, the medical-policy conflict, profoundly impacted healthcare delivery.
Soon Sun Kim   +24 more
doaj   +1 more source

A time to act: improving liver health and outcomes in liver disease

open access: yes, 2009
A report prepared by the British Association for the Study of the Liver (BASL) and the British Society of Gastroenterology (BSG) Liver ...
Sheron, Nick
core   +1 more source

CD4+CD25+CD127low regulatory T cells play predominant anti-tumor suppressive role in hepatitis B virus associated hepatocellular carcinoma

open access: yesFrontiers in Immunology, 2015
Background:Hepatocellular carcinoma (HCC) is the second leading cause of cancer death worldwide and hepatitis B is one of the commonest causes. T regulatory cells (Tregs) are strong immunomodulators and are likely to play a major role in HCC development.
Shreya eSharma   +10 more
doaj   +1 more source

The impact of thrombocytopenia on prognosis of HBV-related small hepatocellular carcinoma: a propensity score matching analysis

open access: yesWorld Journal of Surgical Oncology, 2021
Background Thrombocytopenia was reported both detrimental and advantageous to hepatocellular carcinoma (HCC). However, there is little evidence showing clearly the clinical value of preoperative thrombocytopenia on the surgical outcome of patients with ...
Wei Peng   +4 more
doaj   +1 more source

Post-Transcriptional Regulation of Hepatic DDAH1 with TNF Blockade Leads to Improved eNOS Function and Reduced Portal Pressure In Cirrhotic Rats

open access: yesScientific Reports, 2017
Portal hypertension (PH) is a major cause of morbidity and mortality in chronic liver disease. Infection and inflammation play a role in potentiating PH and pro-inflammatory cytokines, including TNF, are associated with severity of PH.
V. Balasubramanian   +6 more
doaj   +1 more source

Toripalimab combined with lenvatinib and GEMOX is a promising regimen as first-line treatment for advanced intrahepatic cholangiocarcinoma: a single-center, single-arm, phase 2 study

open access: yesSignal Transduction and Targeted Therapy, 2023
Advanced intrahepatic cholangiocarcinoma (ICC) has a dismal prognosis. Here, we report the efficacy and safety of combining toripalimab, lenvatinib, and gemcitabine plus oxaliplatin (GEMOX) as first-line therapy for advanced ICC.
Guo-Ming Shi   +22 more
doaj   +1 more source

Home - About - Disclaimer - Privacy